Oncopeptides strengthens the leadership of its European operations by appointing Andrea Passalacqua as General Manager in Europe, and Pamela Bacon as Head of Medical Affairs Europe.
Paula Boultbee, Chief Commercial Officer since 2016, has decided to retire after 30 years in leading oncology marketing roles. Paula played an instrumental role early in the company’s commercial evolution, helping to establish Oncopeptides Inc. and paving the way for the launch of PEPAXTO (melphalan flufenamide) in the US and potentially other geographies.
In his capacity as General Manager in Europe, Andrea Passalacqua will be part of the global Leadership Team of Oncopeptides AB. Andreas brings extensive commercial experience from Amgen and Celgene in multiple myeloma, and most recently he served as General Manager in Italy for Bluebird Bio, states the company.
“I am looking forward to contributing to the continued success of Oncopeptides by building and leading a dedicated commercial organization in Europe,” says Andrea Passalacqua, General Manager in Europe, at Oncopeptides. “Melphalan flufenamide has the potential to address a growing medical need in relapsed or refractory multiple myeloma and thus bringing significant clinical value and hope to myeloma patients.”
Pamela Bacon carries a significant proficiency in the multiple myeloma space and has an in-depth experience from several global Medical Affairs roles within Celgene and Amgen.
“This is a very exciting time to join Oncopeptides,” says Pamela Bacon, Head of Medical Affairs in Europe. “During the recent years Oncopeptides has executed a comprehensive clinical program in multiple myeloma. It’s my ambition to further anchor this with Key Opinion Leaders and prepare the ground for a Conditional Marketing Authorization in Europe.”
Photo of Andrea Passalacqua: Oncopeptides